Industry News

- Read more about For diagnosis of chronic lymphocytic leukaemia, Multiplicom announce CLL MASTR Plus kit
Multiplicom N.V., announced the launch of a new gene panel, the CLL MASTR Plus kit, to improve the diagnosis of patients with chronic lymphocytic leukaemia.
- Read more about Zydus receives US FDA marketing nod for morphine sulfate ER tablets
US Food and Drug Administration (FDA) has granted marketing authorisation for morphine sulfate ER tablets. A subsidiary of Zydus Pharmaceuticals (USA) Inc., Nesher has considerable expertise in niche therapies with development or products barriers, such as controlled release medications and DEA-controlled substances. Morphine sulfate ER tablets used in the treatment of chronic pain or cancer related pain. The product will be manufactured at Nesher Pharmaceuticals (USA) LLC, located at St. Louis, USA.
- Read more about FSSAI stop manufacture, sale, distribution and import of Mulmin Vitamin Drops
'Mulmin vitamin drops' is a combination of synthetic vitamins and minerals meant for children of one year age. However, the Food Safety and Standards Authority of India (FSSAI) issued a notice to the company to stop manufacture, sale, distribution and import of Mulmin drops and recall the existing products from the market with immediate effect.
- Read more about Hilleman Labs’ provide preclinical trial report on Hib vaccine
Hilleman Laboratories is a first-of-its-kind joint-venture partnership formed between Merck & Co., a global research-driven pharmaceutical organization and Wellcome Trust, a global charitable foundation dedicated to human and animal health by supporting the brightest minds. Hilleman Laboratories (HL) claimed to have made a break-through research on the success of a preclinical trial conducted for Haemophilus influenza type b (Hib) vaccine offering hope to millions of children and needy people. Hilleman Laboratories announced the publication of an original scientific report in the journal 'Vaccine' based on the success of a pre-clinical trial conducted for the vaccine.
- Read more about UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services
(NewsVoir); UCB, a multinational biopharmaceutical company, and Genpact (NYSE: G), a global leader in designing, transforming, and running intelligent business operations, have received the Aecus Innovation Award in recognition of their close collaboration in driving transformation that achieved far-reaching operational efficiencies in UCB’s global business services (GBS) finance organization.
- Read more about Saint Louis University in the US Developed New Class of Cancer Drugs
A new study conducted at Saint Louis University has found a way to stop cancer cell growth. The study appeared in Cancer Cell.

"Cancer cells look for metabolic pathways to find the parts to grow and divide. If they don't have the parts, they just die," said Thomas Burris, chair of pharmacology and physiology at Saint Louis University, US.
- Read more about Ricoh India present ‘Picasso’ medical imaging solution in Hyderabad
Ricoh India, a wholly-owned subsidiary of Japanese imaging and electronics major Ricoh, launched a new medical imaging solution called ‘Picasso’ (Patient is Central to this Advanced Solution and Service Offering) recently in Hyderabad. Picaso is web-based multi-specialty cloud-enabled imaging solution. The new innovative medical imaging solution is designed to offer benefits to patients, radiologists, consultants and hospitals and drastic reduction in the healthcare costs for the patients.
- Read more about Jubilant's anti-infection drug receive US regulator nod
Jubilant Life Sciences has announced that it had received approval of the US Food and Drug Administration (FDA) for its tablets used in treating adults for various infections, including pneumonia. The market size for Levofloxacin is estimated to be $28 million (Rs.179 crore) per annum.
- Read more about TAKE Solutions receive US patent for optimising clinical data standardization method
TAKE Solutions Ltd., a global business technology solutions provider, was awarded a patent by the United States Patent and Trademark Office (USPTO) for its "Method for Optimizing Clinical Data Standardization". It provides cost-effective and comprehensive solutions for enterprises across diverse sectors including pharmaceuticals, high technology, consumer packaged goods. TAKE’s global headquarters is in Chennai, India; its US headquarters is located in Princeton, New Jersey. This process leverages TAKE Solutions’ clinical accelerators to reduce the time taken to standardize trial data by over 50% (when compared to standardization without the accelerators), thus reducing time to market.

[adsense:336x280:8701650588]
- Read more about Daiichi Sankyo, Maruishi Pharma entered into agreement to commercialize remifentanil injection
Maruishi Pharmaceutical Co., Ltd. & Daiichi Sankyo Company, Limited, a global pharmaceutical company Collaborate to commercialize the general anaesthesia analgesic, remifentanil injection generic. Maruishi Pharmaceutical is currently applying for a manufacture and marketing license. Once Maruishi Pharmaceutical has acquired a license for the manufacturing and marketing of this drug, the plan is for Maruishi Pharmaceutical to handle its manufacture and Daiichi Sankyo to handle its marketing, while both companies will jointly conduct promotion activities.